OPS
BCRX icon

Orion Portfolio Solutions’s BioCryst Pharmaceuticals BCRX Stock Holding History

Orion Portfolio Solutions’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,864
Closed -$188K – 642
2021
Q2 		$188K Sell
11,864
-11,600
-49% -$158K 0.01% 595
2021
Q1 		$239K Buy
23,464
+2,768
+13% +$28.5K 0.01% 479
2020
Q4 		$154K Buy
20,696
+695
+3% +$3.58K 0.01% 486
2020
Q3 		$69K Buy
+20,001
New +$85.7K ﹤0.01% 435
2020
Q1 		– Sell
-100
Closed – – 1912
2019
Q4 		$0 Buy
+100
New +$252 ﹤0.01% 1810

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Orion Portfolio Solutions's BCRX Position: Q3 2021 in Review

Orion Portfolio Solutions sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2021, closing a stake of 11,864 shares — an estimated $188K sold.

Orion Portfolio Solutions first reported a position in BCRX in Q4 2019 and held it in 5 quarters. The position peaked at $239K in Q1 2021. 197 funds tracked by Wall St. Rank hold BCRX as of Q3 2021.

  • Orion Portfolio Solutions reported no remaining BioCryst Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Orion Portfolio Solutions sold 11,864 BioCryst Pharmaceuticals shares in Q3 2021, an estimated $188K.
  • Orion Portfolio Solutions first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Orion Portfolio Solutions's BioCryst Pharmaceuticals position peaked at $239K in Q1 2021.
  • 197 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2021.

Based on Orion Portfolio Solutions's 13F filing for Q3 2021, filed 10 Nov 2021.